On Monday, Citi initiated coverage on BioAge Labs Inc (NASDAQ:BIOA) shares, giving the biotech company a Buy rating and setting a price target of $45.00. The firm highlighted BioAge's focus on developing treatments for metabolic diseases, particularly noting the potential of its leading drug candidate, azelaprag.
Azelaprag, an oral small molecule agonist of the apelin receptor, is currently in a Phase 2 clinical trial named STRIDES, which is investigating its efficacy in combination with tirzepatide for obesity treatment. The trial is expected to provide top-line proof-of-concept data in the third quarter of 2025.
Citi's positive outlook on BioAge Labs is based on several factors. The analyst pointed out that azelaprag is not only orally administered and easily manufactured but also has shown a good safety profile across multiple clinical studies. The preclinical data suggests that azelaprag could have an attractive clinical profile for treating obesity.
Moreover, the drug's novel mechanism of action (MOA) is seen as a potential advantage, as it could be used in combination with incretins or other treatments currently in development. The interest in the obesity treatment landscape among pharmaceutical companies also leads Citi to consider BioAge Labs as a possible target for mergers and acquisitions, should the drug's proof-of-concept be successful.
The firm concluded its analysis with an optimistic stance, initiating coverage with a Buy rating and a high-risk designation, alongside the $45 price target for BioAge Labs shares.
In other recent news, BioAge Labs Inc. has received positive ratings from two major financial institutions. Jefferies initiated coverage on BioAge Labs with a Buy rating and a $42 price target, highlighting the potential of the company's leading drug candidate, Azelaprag.
The drug, currently undergoing two Phase 2 trials, is expected to provide significant weight loss benefits and has the potential to generate approximately $1.8 billion in total peak adjusted revenue, according to the analyst's model.
Simultaneously, Morgan Stanley initiated coverage on the company with an Overweight rating and a $40 price target, citing BioAge's promising early data on weight loss and body composition improvements. The company's strategic partnership with pharmaceutical titan Eli Lilly (NYSE:LLY), involving assistance with study design and execution, was also noted as a crucial part of BioAge's strategy.
These recent developments reflect the robust validation of BioAge's research and development efforts, and suggest potential commercial opportunities for the company's therapies in the future. The results from the ongoing trials are anticipated in the third quarter of 2025 and the second half of 2026, respectively.
InvestingPro Insights
Adding to Citi's optimistic outlook on BioAge Labs Inc (NASDAQ:BIOA), recent data from InvestingPro provides additional context for investors. The company's market capitalization stands at $854.6 million, reflecting the market's current valuation of its potential in the competitive biotech landscape.
InvestingPro Tips highlight that BioAge holds more cash than debt on its balance sheet, which could be crucial for funding its ongoing clinical trials, particularly the STRIDES study for azelaprag. This financial stability aligns with Citi's positive view on the company's prospects.
However, it is important to note that BioAge is not currently profitable, with an adjusted operating income of -$51.56 million over the last twelve months as of Q2 2024. This is typical for biotech companies in the development stage and underscores the importance of successful clinical outcomes for drugs like azelaprag.
Interestingly, BioAge's stock has shown strong performance recently, with a 30.31% return over the last month. This aligns with the InvestingPro Tip indicating that the stock is trading near its 52-week high, possibly reflecting investor optimism about the company's pipeline and Citi's recent coverage initiation.
For investors seeking a deeper understanding of BioAge's potential, InvestingPro offers 10 additional tips, which could provide valuable insights into the company's financial health and market position as it progresses through clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.